Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era
The classical bimodal recurrence pattern of hepatocellular carcinoma following curative treatment was established prior to the widespread use of effective antiviral therapy. It is unclear whether this recurrence pattern is still valid in the era of effective antiviral therapy. The current study shows that antiviral therapy can reduce late recurrence, resulting in loss of the second peak of the classical bimodal recurrence pattern. This study provides further evidence highlighting the importance of adherence to antiviral therapy in patients who received curative treatment for hepatocellular carcinoma.
Authors
- Janet W.C. Kung (ORCID: https://orcid.org/0000-0003-4647-0254)
- Frankie Mo (ORCID: https://orcid.org/0000-0002-0566-3212)
- Kevin Mok (ORCID: https://orcid.org/0000-0002-3638-3395)
- Molly Li (ORCID: https://orcid.org/0000-0002-6460-5514)
- Chung‐Ming Chu (ORCID: https://orcid.org/0000-0002-9959-1271)
- Terry Cheuk‐Fung Yip (ORCID: https://orcid.org/0000-0002-1819-2464)
- Landon L. Chan (ORCID: https://orcid.org/0000-0002-1306-5896)
- Stephen L. Chan (ORCID: https://orcid.org/0000-0001-8998-5480)
- Ksh Chok (ORCID: https://orcid.org/0000-0001-7921-3807)
- Grace Lai–Hung Wong (ORCID: https://orcid.org/0000-0002-2863-9389)
- Vincent Wai‐Sun Wong (ORCID: https://orcid.org/0000-0003-2215-9410)
- Anthony W.H. Chan (ORCID: https://orcid.org/0000-0002-1771-163X)
- A. Ngai
Institutions
- Chinese University of Hong Kong (HK)
- Prince of Wales Hospital (CN)
Publication Details
- Journal
- Journal of Hepatology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1016/j.jhep.2025.05.028
- Citations
- 4
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 5.56
Funders
- AstraZeneca
- Gilead Sciences
- Eisai
- Ipsen